Validation for safety and efficacy of axillary reverse mapping using ICG in terms of prevention for lymphedema of upper limb in breast cancer

Validation for safety and efficacy of axillary reverse mapping using ICG in terms of prevention for lymphedema of upper limb in breast cancer - Validation for safety and efficacy of axillary reverse mapping using ICG

Status

Active, not recruiting

Phases

Phase 1

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000031880

Enrollment

Registered

2018-03-26

Start date

2020-06-02

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

breast cancer

Interventions

We would detect lymph ducts from upper limb during axillary lymph node dissection and preserve the lymph ducts.

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: patients who will be performed axillary lymph node dissection with clinically metastasis-positive status in axillary lymph nodes or metastasis positive status proven by a sentinel lymph node biopsy.

Exclusion criteria

Exclusion criteria: patients with sensitivity to ICG or other drugs pregnant patients

Design outcomes

Primary

Measure	Time frame
percentage of lymph edema in upper limb adverse events	—

Secondary

Measure	Time frame
percentage of detection of lymph ducts detail of lymph ducts local recurrence rate of axillary lymph nodes	—

Countries

Japan

Contacts

Public ContactRyota Otsubo

Nagasaki University Hospital Surgical Oncology

rotsubo@nagasaki-u.ac.jp095-819-7304

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026